Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "Therefore, we designed a trial to test we's hypothesis that early administration of dexamethasone in combination with immunoglobulin (IV)-IG) and interferon-beta can reduce the effect of the ensuing cytokine storm in critically ill patients COVID-19." provenance.
- SENTENCE label "dexamethasone failed to demonstrate any protective advantage in terms of mitigating short-term PMCs or infectious complications, or to confer any long-term survival benefit." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "We postulated that adjunctive treatment of established ARDS caused by the coronavirus disease 2019 (COVID)-19) with intravenous dexamethasone might change the pulmonary and systemic inflammatory response and thereby reduce morbidity, leading to a decrease in duration of mechanical ventilation and in mortality." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "In summary, a number of corticosteroids, including and especially methylprednisolone and dexamethasone, have demonstrated remarkable efficacy, particularly for COVID-19 patients who underwent mechanical ventilation." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Therefore, low-dose dexamethasone may be used in obese children for PONV prophylaxis." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Administration of dexamethasone to mitigate postoperative nausea and vomiting has been suggested to improve short- and long-term outcomes after pancreatic ductal adenocarcinoma (PDAC) resection." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "Intraoperative dexamethasone was not associated with differences in postoperative major complications (PMCs) (21.1 vs 19.3%; p = 0.68), postoperative pancreatic fistulas (6.3 vs 6.7%; p = 0.88), or composite infectious complications (28.7 vs 24.7%; p = 0.39)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "dexamethasone was not associated with any improvement in median recurrence-free survival (RFS) (17 vs 17 months; p = 0.99) or overall survival (OS) (46 vs 43 months; p = 0.90)." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "Moreover, dexamethasone effectively suppressed exogenous BID expression and the antitumor effect of a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells both in vitro and in vivo." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.
- SENTENCE label "In our previous basic studies, anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone) inhibited the process of exocytosis and showed anti-allergic drugs (olopatadine, ketotifen), antibiotics (clarithromycin) and corticosteroids (hydrocortisone, dexamethasone)'s potency as highly effective mast cell stabilizers." provenance.